However, a specific focus on patients with ES-SCLC revealed the prolongation of median OS among patients positive for PD-L1 expression relative to patients that were PD-L1-negative (9.2 months vs. 5.4 months, P = 0.037), whereas no significant difference in median PFS was evident between these groups (5.2 months vs. 4.6 months, P = 0.747) (35). This evidence concerns the gene CD274 and small cell lung carcinoma.